文献速递脑血管病

替奈普酶静脉溶栓治疗急性缺血性卒中

Intravenous Thrombolysis with Tenecteplase for the Treatment of Acute Ischemic Stroke.
PubMed 文献 · Ann Neurol · 2022-07-07

该研究基于SITS-ISTR注册数据,采用倾向评分匹配比较替奈普酶与阿替普酶静脉溶栓的安全性及有效性。331例替奈普酶治疗患者与797例阿替普酶治疗患者匹配,替奈普酶组3个月功能结局更优(共同OR=1.54,95%CI=1.18-2.00),全因死亡率更低(OR=0.43,95%CI=0.27-0.67),24小时症状性颅内出血无差异。

要点

  • 替奈普酶静脉溶栓与阿替普酶相比,3个月功能结局更优(共同OR=1.54,95%CI=1.18-2.00)。
  • 替奈普酶组3个月全因死亡率更低(OR=0.43,95%CI=0.27-0.67)。
  • 两组24小时症状性颅内出血率无显著差异(1.0% vs 1.3%,OR=0.72,95%CI=0.20-2.64)。

核心结论

  • 在急性缺血性卒中患者中,替奈普酶静脉溶栓与阿替普酶相比与更好的3个月临床结局相关,且未增加症状性颅内出血风险。

研究设计与样本

  • 研究基于参与SITS-ISTR注册的20个中心的数据,采用倾向评分匹配分析,将接受替奈普酶静脉溶栓的患者与来自同一中心的最多3例接受阿替普酶静脉溶栓的患者进行匹配。

主要发现

  • 共有331例替奈普酶治疗的急性缺血性卒中患者与797例阿替普酶治疗患者匹配(中位年龄70岁,女性43.9%,中位NIHSS评分11,四分位距6-17)。
  • 替奈普酶组3个月功能结局分布优于阿替普酶组(共同OR=1.54,95%CI=1.18-2.00)。
  • 替奈普酶组3个月良好功能结局(mRS评分=0-2)的比值比高于阿替普酶组(OR=2.00,95%CI=1.45-2.77)。
  • 替奈普酶组3个月全因死亡率的比值比低于阿替普酶组(OR=0.43,95%CI=0.27-0.67)。
  • 两组3个月极好功能结局(mRS评分=0-1)的比值比无显著差异(OR=1.31,95%CI=0.96-1.78),24小时症状性颅内出血率无显著差异(1.0% vs 1.3%,OR=0.72,95%CI=0.20-2.64)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Intravenous thrombolysis (IVT) with tenecteplase has been associated with better clinical outcomes in acute ischemic stroke (AIS) patients with confirmed large vessel occlusions compared to IVT with alteplase. However, the utility of tenecteplase for the treatment of all AIS patients eligible for IVT has not been established. METHODS: We compared the safety and efficacy of tenecteplase versus alteplase in AIS patients by analyzing propensity score matched data from 20 centers participating in the Safe Implementation of Treatments in Stroke-International Stroke Thrombolysis Register. Patients receiving IVT with tenecteplase were matched with up to 3 patients receiving alteplase from the same center. The primary outcome of interest was the distribution of 3-month functional outcomes. Secondary outcomes included the rates of patients with symptomatic intracranial hemorrhage (SICH) in the first 24 hours, excellent (modified Rankin Scale [mRS] score = 0-1) or good (mRS score = 0-2) functional outcome, and all-cause mortality at 3 months. RESULTS: A total of 331 tenecteplase-treated AIS patients were matched to 797 patients treated with alteplase (median age = 70 years, 43.9% women, median National Institutes of Health Stroke Scale score = 11, interquartile range = 6-17). Patients treated with tenecteplase had better 3-month functional outcomes (common odds ratio [OR] = 1.54, 95% confidence interval [CI] = 1.18-2.00) with higher odds of good functional outcome (OR = 2.00, 95% CI = 1.45-2.77) and a lower likelihood of all-cause mortality (OR = 0.43, 95% CI = 0.27-0.67) at 3 months, compared to alteplase-treated patients. No difference was found in the likelihood of the 3-month excellent functional outcomes (OR = 1.31, 95% CI = 0.96-1.78) and 24-hour SICH (1.0% vs 1.3%, OR = 0.72, 95% CI = 0.20-2.64). INTERPRETATION: IVT with tenecteplase was associated with better 3-month clinical outcomes compared to IVT with alteplase in AIS patients, with no increased risk of symptomatic intracranial bleeding. ANN NEUROL 2022;92:349-357.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Tsivgoulis G, Katsanos AH, Christogiannis C, et al. Intravenous Thrombolysis with Tenecteplase for the Treatment of Acute Ischemic Stroke. Ann Neurol. 2022. PMID: 35713213. doi:10.1002/ana.26445

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。